Enlivex (ENLV) said the U.S. FDA granted RMAT (Regenerative Medicine Advanced Therapy) designation to Allocetra for the treatment of age-related symptomatic knee, a positive regulatory milestone that can support expedited development and review. The announcement is likely to modestly improve market sentiment around the program’s prospects.
Enlivex (ENLV) said the U.S. FDA granted RMAT (Regenerative Medicine Advanced Therapy) designation to Allocetra for the treatment of age-related symptomatic knee, a positive regulatory milestone that can support expedited development and review. The announcement is likely to modestly improve market sentiment around the program’s prospects.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
